Pharmaceutical giants Pfizer and Bristol-Myers Squibb have agreed to work together to research and develop treatments for diabetes and obesity.
Pfizer already has a DGAT-1 inhibitor programme in place which it is hoped will lead to breakthroughs in helping people with the metabolic disorders.
Under the terms of the agreement, Pfizer will be responsible for all research and early-stage development, and the companies will jointly conduct phase III trials and commercial activities.
B-MS chief scientific officer Elliott Sigal said: “The worldwide incidence of metabolic disorders is increasing rapidly, and complications from diabetes and obesity are leading causes of disability and mortality globally.
“DGAT-1 inhibitors have shown promise in preclinical testing, and this research programme has potential to yield several compounds that may improve treatment options for patients.
“This collaboration underscores the company’s commitment to investing in research and development, and reflects our strategy to identify partnerships that complement our own research efforts to enhance our innovative pipeline.”
Dr Ed Harrigan, senior vice-president of Pfizer Worldwide Business Development, said: “This agreement is one part of a collaborative relationship with Bristol-Myers Squibb which combines the strengths of both companies in the development of two promising research programmes.
“Pfizer continues to look for new strategic opportunities to complement our portfolio of medicines and drive long-term growth of the company.”
Copyright © PA Business 2007
Bristol-Myers Squibb: www.bms.com/landing/data/index.html